Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ALG-020572
- Development stage
- Discontinued
- Lead developer
- Aligos Therapeutics
- Modality
- MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Modified DNA Oligonucleotides → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Subcutaneous
01
Overview
ALG-020572 is a GalNAc-conjugated antisense oligonucleotide (ASO) developed for the treatment of chronic hepatitis B. It is an 18-mer phosphorothioated ASO containing novel bridged nucleic acid/DNA modifications, designed to selectively bind to and degrade viral messenger RNA complementary to the hepatitis B surface antigen (HBsAg) region, thereby reducing HBsAg levels in patients. The drug utilizes third-generation XNA chemistry and GalNAc conjugation for enhanced hepatocyte targeting and improved pharmacological properties. Despite promising preclinical results, clinical development was terminated due to unexpected liver toxicity observed in early-phase trials[1][3][4][5][6].
Beyond the preview
Go deeper on ALG-020572.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ALG-020572.